Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888110 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL18576747 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1908521 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231410 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL21572792 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1232158 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231592 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL12888104 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231595 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231435 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118291560-A | Synthesis method of sabatier intermediate (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4- ((tert-butoxycarbonyl) amino) -2-methyl ethyl valerate | 江苏德源药业股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-118516422-A | Method for synthesizing Sha Kuba koji intermediate by biocatalysis | 江苏海洋大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-118291560-A | Synthesis method of sabatier intermediate (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4- ((tert-butoxycarbonyl) amino) -2-methyl ethyl valerate | 江苏德源药业股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118109529-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl ethyl valerate serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118109528-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | disclosed |
| EP-2890672-B1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017141193-A1 | PROCESS FOR THE PREPARATION OF SACUBITRIL OR SALTS THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-08-24 | — | — | WO | disclosed |
| US-9624163-B2 | Process for preparing intermediates useful in the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624163-B2 | Process for preparing intermediates useful in the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| EP-2245009-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2009090251-A2 | NEW PROCESSES | NOVARTIS AG (CH) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008031567-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | MME 1/4885ACE 6/4885MMEL1 90/4885 |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | MME 1/4885ACE 5/4885MMEL1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.